Physician profile
Steven Parker
NPI 1750309811
$6,099.41
in general payments reported to CMS, 2019-2025
32 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $696 · 2021: $2,280 · 2022: $637 · 2023: $778 · 2024: $538 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,374.08 | 2021 | |
| Abbvie INC. | $542.29 | 2021-2025 | |
| Allergan, INC. | $515.96 | 2019-2020 | |
| Viiv Healthcare Company | $491.15 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $486.81 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| La Jolla Pharmaceutical Company | $484.36 | 2021-2025 | Xerava, Xacduro |
| Gilead Sciences, INC. | $276.00 | 2019-2024 | Veklury |
| Astellas Pharma US INC | $261.35 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $206.62 | 2020-2025 | Nuzyra |
| Pfizer INC. | $206.01 | 2019-2023 | |
| Janssen Products, LP | $198.00 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $159.10 | 2019-2020 | |
| Janssen Biotech, INC. | $149.72 | 2019-2022 | |
| Insmed, INC. | $106.04 | 2024-2025 | Arikayce |
| Aimmune Therapeutics, INC. | $87.71 | 2024-2025 | Vowst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $77.09 | 2021 | |
| Shionogi INC | $52.08 | 2023-2024 | Fetroja |
| Theratechnologies INC. | $49.46 | 2021 | |
| Grifols USA, LLC | $48.53 | 2023 | Gamunex-C |
| Biotissue Holdings INC. | $44.59 | 2022 | |
| Tactile Systems Technology INC | $40.65 | 2020-2022 | |
| Adma Biomanufacturing LLC | $35.01 | 2021 | |
| Ferring Pharmaceuticals INC. | $33.04 | 2023 | Rebyota |
| Amgen INC. | $25.67 | 2024 | Actimmune |
| Horizon Therapeutics Plc | $24.99 | 2022 | |
| Bio Products Laboratory USA, INC. | $21.40 | 2022 | |
| Kerecis Limited | $21.15 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Cumberland Pharmaceuticals, INC. | $17.89 | 2024 | Vibativ |
| Melinta Therapeutics, LLC | $17.16 | 2019 | |
| Mylan Specialty L.P. | $15.78 | 2019 | |
| Shire North American Group INC | $14.94 | 2019 | |
| Glaxosmithkline, LLC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.